Objective:To develop a patient-reported traditional Chinese medicine kidney deficiency pattern(TCMKDP)scale for colorectal cancer(CRC)patients and evaluate its reliability and validity.Methods:We administered the TCM-...Objective:To develop a patient-reported traditional Chinese medicine kidney deficiency pattern(TCMKDP)scale for colorectal cancer(CRC)patients and evaluate its reliability and validity.Methods:We administered the TCM-KDP questionnaire to postoperative patients with stage II and III CRC as part of a multicenter randomized controlled trial(RCT)conducted in China from December 2018 to September 2021.The TCM-KDP scale consists of eight items on patient-reported symptoms and is scored on a five-point Likert scale.The scale’s reliability was assessed using Cronbach’s a and test-retest reliability,while content validity was evaluated with the content validity index.We compared the differences in serum cytokine levels and other clinical factors between patients with higher and lower KDP scores.Results:Of the 378 patients analyzed in the original RCT,352(93.2%)completed the TCM-KDP questionnaire.The Cronbach’s a of the eight-item TCM-KDP scale was 0.734,and the test-retest reliability was 0.745.Our exploratory factor analysis yielded eight factors that explained the variance of 50.34%.The mean TCM-KDP score was 2.80±0.92.Compared with patients with stage II CRC,those with stage III CRC had significantly higher TCM-KDP scores(2.25 vs.2.50,P=.026).We categorized all patients into highor low-KDP score groups(the cut-off score was 2.8).Patients with lower TCM-KDP scores had significantly higher serum interleukin-1b expression levels(P=.04).Conclusion:The patient-reported TCM-KDP scale demonstrated relatively good feasibility,internal consistency,and test-retest reliability among patients with CRC.Future studies could apply this scale to other cancer types and diseases.展开更多
Objective:To explore the kidney yang deficiency pattern(KYDP)in a chronic kidney disease(CKD)rat model and the mechanisms underlying the effects of Zhenwu decoction(ZWD)by conducting tran-scriptomic and metabolomic an...Objective:To explore the kidney yang deficiency pattern(KYDP)in a chronic kidney disease(CKD)rat model and the mechanisms underlying the effects of Zhenwu decoction(ZWD)by conducting tran-scriptomic and metabolomic analyses.Methods:Adriamycin(ADR)combined with hydrocortisone(HC)was used to induce CKD with KYDP in rats.ADR was injected into the tail vein twice.HC was injected intramuscularly for 8 weeks.ZWD was administered by gavage for 8 weeks.The general condition was observed,24-h urine protein was detected,serum corticosterone,triiodothyronine,thyroxine,TSH,testosterone,cAMP,and cGMP levels were determined,and pathological analysis was conducted.Transcriptomic and metabolomic analyses were conducted to screen differentially expressed genes(DEGs),differentially expressed metabolites(DEMs),and differentially expressed pathways(DEPs).The core DEMs and DEGs were input to Metab-oanalyst 5.0 to identify the pathways affected by ZWD.Results:In the HC group,KYDP symptoms were observed.Compared with control group,the levels of 24-h urine protein,TSH,and cGMP significantly increased(all P<0.01),and corticosterone,triiodothyronine,thyroxine,and cAMP significantly decreased(all P<0.01)in the HC group.After ZWD intervention,the levels of above-mentioned indicators could be reversed to some extent.Pathological analysis in the HC group revealed kidney lesions.DEGs in the ZWD group were mainly associated with pathways such as nucleotide synthesis and endocrine pathways.In the ZWD group,differences in biosynthesis of unsat-urated fatty acids and butanoate metabolism were observed.The following pathways were significantly affected by ZWD:arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism.Conclusion:ZWD can be used to treat KYDP in CKD through regulating arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism.展开更多
基金supported by Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences,Youth Program(C12021A01819)China National Key R&D Plan Special Program for Modernization of Traditional Chinese Medicine,Ministry of Science and Technology of the People’s Republic of China,2017YFC1700604+1 种基金Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences(CI2021B009)Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202205).
文摘Objective:To develop a patient-reported traditional Chinese medicine kidney deficiency pattern(TCMKDP)scale for colorectal cancer(CRC)patients and evaluate its reliability and validity.Methods:We administered the TCM-KDP questionnaire to postoperative patients with stage II and III CRC as part of a multicenter randomized controlled trial(RCT)conducted in China from December 2018 to September 2021.The TCM-KDP scale consists of eight items on patient-reported symptoms and is scored on a five-point Likert scale.The scale’s reliability was assessed using Cronbach’s a and test-retest reliability,while content validity was evaluated with the content validity index.We compared the differences in serum cytokine levels and other clinical factors between patients with higher and lower KDP scores.Results:Of the 378 patients analyzed in the original RCT,352(93.2%)completed the TCM-KDP questionnaire.The Cronbach’s a of the eight-item TCM-KDP scale was 0.734,and the test-retest reliability was 0.745.Our exploratory factor analysis yielded eight factors that explained the variance of 50.34%.The mean TCM-KDP score was 2.80±0.92.Compared with patients with stage II CRC,those with stage III CRC had significantly higher TCM-KDP scores(2.25 vs.2.50,P=.026).We categorized all patients into highor low-KDP score groups(the cut-off score was 2.8).Patients with lower TCM-KDP scores had significantly higher serum interleukin-1b expression levels(P=.04).Conclusion:The patient-reported TCM-KDP scale demonstrated relatively good feasibility,internal consistency,and test-retest reliability among patients with CRC.Future studies could apply this scale to other cancer types and diseases.
基金This study was supported by the National Key Research and Development Program of the Ministry of Science and Technology of the People's Republic of China(2018YFC1704304).
文摘Objective:To explore the kidney yang deficiency pattern(KYDP)in a chronic kidney disease(CKD)rat model and the mechanisms underlying the effects of Zhenwu decoction(ZWD)by conducting tran-scriptomic and metabolomic analyses.Methods:Adriamycin(ADR)combined with hydrocortisone(HC)was used to induce CKD with KYDP in rats.ADR was injected into the tail vein twice.HC was injected intramuscularly for 8 weeks.ZWD was administered by gavage for 8 weeks.The general condition was observed,24-h urine protein was detected,serum corticosterone,triiodothyronine,thyroxine,TSH,testosterone,cAMP,and cGMP levels were determined,and pathological analysis was conducted.Transcriptomic and metabolomic analyses were conducted to screen differentially expressed genes(DEGs),differentially expressed metabolites(DEMs),and differentially expressed pathways(DEPs).The core DEMs and DEGs were input to Metab-oanalyst 5.0 to identify the pathways affected by ZWD.Results:In the HC group,KYDP symptoms were observed.Compared with control group,the levels of 24-h urine protein,TSH,and cGMP significantly increased(all P<0.01),and corticosterone,triiodothyronine,thyroxine,and cAMP significantly decreased(all P<0.01)in the HC group.After ZWD intervention,the levels of above-mentioned indicators could be reversed to some extent.Pathological analysis in the HC group revealed kidney lesions.DEGs in the ZWD group were mainly associated with pathways such as nucleotide synthesis and endocrine pathways.In the ZWD group,differences in biosynthesis of unsat-urated fatty acids and butanoate metabolism were observed.The following pathways were significantly affected by ZWD:arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism.Conclusion:ZWD can be used to treat KYDP in CKD through regulating arachidonic acid metabolism,valine,leucine,and isoleucine biosynthesis,linoleic acid metabolism,and alpha-linolenic acid metabolism.
